Showing 40,261 - 40,280 results of 105,070 for search '(( 5 ((((a decrease) OR (we decrease))) OR (mean decrease)) ) OR ( e point decrease ))', query time: 2.10s Refine Results
  1. 40261

    Description of the role of the pharmacist in a multiprofessional team focused on the care of hospitalized elderly by Isabela Vaz Leite Pinto (12817700)

    Published 2022
    “…A total of 163 pharmaceutical interventions were carried out, representing a mean of 6.79 interventions/patient and 82.2% acceptance. …”
  2. 40262
  3. 40263

    Supplementary Material for: Group- and Home-Based Cognitive Intervention for Patients with Mild Cognitive Impairment: A Randomized Controlled Trial by Jeong J.H. (3199218)

    Published 2016
    “…<b><i>Results:</i></b> In comparison to the controls (a 0.8-point decrease), the subjects receiving GCI (a 2.3-point decrease, p = 0.01) or HCI (a 2.5-point decrease, p = 0.02) showed significant improvements in the modified ADAS-Cog at PI, respectively. …”
  4. 40264
  5. 40265

    Diabetes, Drug Treatment and Mortality in COVID-19: A Multinational Retrospective Cohort Study by Jennifer E. Nyland (11412878)

    Published 2021
    “…Glucose-regulating medications such as glucagon-like peptide-1 receptor (GLP-1R) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and pioglitazone are known to have anti-inflammatory effects that may improve outcomes in patients with SARS-CoV-2 infection. In a multinational retrospective cohort study, we used the TriNetX COVID-19 Research Network of 56 large healthcare organizations to examine these medications in relation to the incidence of hospital admissions, respiratory complications, and mortality within 28 days following a COVID-19 diagnosis. …”
  6. 40266
  7. 40267
  8. 40268
  9. 40269

    The association between previous and future severe exacerbations of chronic obstructive pulmonary disease: Updating the literature using robust statistical methodology by Mohsen Sadatsafavi (63962)

    Published 2018
    “…We applied a random-effects 'joint frailty' survival model that is particularly developed for the analysis of recurrent events in the presence of competing risk of death and heterogeneity among individuals in their rate of events. …”
  10. 40270
  11. 40271
  12. 40272
  13. 40273
  14. 40274
  15. 40275
  16. 40276
  17. 40277
  18. 40278
  19. 40279
  20. 40280